| 1 |
prostate cancer
(15031 times)
|
Neoplasms
(4627 times)
|
PSA (2060 times)
AR (1057 times)
RP (1040 times)
|
1983 Circadian rhythm in prostatic acid phosphatase (PAP): a potential tumor marker rhythm in prostatic cancer (PCa).
|
| 2 |
prostate carcinoma
(320 times)
|
Neoplasms
(89 times)
|
BPH (73 times)
PSA (43 times)
AR (14 times)
|
1977 Search for oncogenic viruses in human prostate cancer.
|
| 3 |
pancreatic cancer
(109 times)
|
Neoplasms
(33 times)
|
CP (14 times)
OS (6 times)
SBRT (6 times)
|
1998 Quantitative determination of K-ras mutations in pancreatic juice for diagnosis of pancreatic cancer using hybridization protection assay.
|
| 4 |
prostatic adenocarcinoma
(78 times)
|
Pathology
(27 times)
|
BPH (17 times)
HGPIN (16 times)
PSA (16 times)
|
1994 Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP).
|
| 5 |
prostate adenocarcinoma
(71 times)
|
Neoplasms
(19 times)
|
BPH (9 times)
PSA (7 times)
GS (5 times)
|
1985 Effect of transfer factor on tumor-associated immunity and tumor growth of the Dunning R-3327G rat prostate adenocarcinoma.
|
| 6 |
pancreatic carcinoma
(18 times)
|
Gastroenterology
(10 times)
|
CP (12 times)
PPJ (7 times)
IPMN (4 times)
|
1991 Serum ribonuclease activity in the diagnosis of pancreatic disease.
|
| 7 |
prostate cancer patients
(12 times)
|
Urology
(4 times)
|
ADT (4 times)
BMD (2 times)
BRFS (2 times)
|
1998 [Metalloproteinases (MMP-1, MMP-3) and their inhibitors (TIMP) in blood plasma of patients with prostate carcinoma].
|
| 8 |
pancreatic adenocarcinoma
(11 times)
|
Gastroenterology
(6 times)
|
CP (5 times)
ACP (1 time)
asTF (1 time)
|
2006 Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation.
|
| 9 |
anti-prostate cancer
(8 times)
|
Neoplasms
(3 times)
|
AI (1 time)
AR (1 time)
ART (1 time)
|
2013 The interactions of dietary tomato powder and soy germ on prostate carcinogenesis in the TRAMP model.
|
| 10 |
prostate cancer cells
(8 times)
|
Neoplasms
(4 times)
|
BMSC (1 time)
BPH (1 time)
CA (1 time)
|
2003 Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death.
|
| 11 |
Parathyroid carcinoma
(6 times)
|
Endocrinology
(4 times)
|
iPTH (2 times)
ALP (1 time)
DSS (1 time)
|
2010 The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma.
|
| 12 |
Plasma calcium
(5 times)
|
Nephrology
(2 times)
|
CaAc (1 time)
DCa (1 time)
FCa45 (1 time)
|
1989 Autotransplantation of avian parathyroid glands: an animal model for studying parathyroid function.
|
| 13 |
parotid carcinoma
(2 times)
|
Radiography
(1 time)
|
PA (2 times)
BCA (1 time)
CT (1 time)
|
2013 Different histological subtypes of parotid gland tumors: CT findings and diagnostic strategy.
|
| 14 |
plasma Ca
(2 times)
|
Veterinary Medicine
(1 time)
|
BR (1 time)
ENa (1 time)
HM (1 time)
|
1988 Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate.
|
| 15 |
plasma ionized calcium
(2 times)
|
Veterinary Medicine
(1 time)
|
ALB (1 time)
BV (1 time)
Ca (1 time)
|
1994 Alterations in blood viscosity in horses competing in cross country jumping.
|
| 16 |
pre-cachexia
(2 times)
|
Nutritional Sciences
(2 times)
|
RCa (2 times)
Ca (1 time)
mGPS (1 time)
|
2016 Use of routinely available clinical, nutritional, and functional criteria to classify cachexia in advanced cancer patients.
|
| 17 |
prostate adenocancer
(2 times)
|
Nephrology
(1 time)
|
BPH (1 time)
PPI (1 time)
RRP (1 time)
|
2013 Continence recovery time after radical prostatectomy: implication of prostatic apical tumor.
|
| 18 |
prostate calculi and prostate cancer
(2 times)
|
Reproductive Medicine
(2 times)
|
GSs (1 time)
PSA (1 time)
TRUS (1 time)
|
2009 Prostate calculi in cancer and BPH in a cohort of Korean men: Presence of calculi did not correlate with cancer risk.
|
| 19 |
prostate cancer adenocarcinoma
(2 times)
|
Neoplasms
(2 times)
|
BPH (1 time)
CBCT (1 time)
CIRT (1 time)
|
1998 Specific transcription factors prognostic for prostate cancer progression.
|
| 20 |
prostatic carcinogenesis and prostate cancer
(2 times)
|
Cell Transformation, Neoplastic
(1 time)
|
CNF1 (1 time)
EMT (1 time)
PSCA (1 time)
|
2016 Knockdown of PSCA induces EMT and decreases metastatic potentials of the human prostate cancer DU145 cells.
|
| 21 |
pulmonary arterial compliance
(2 times)
|
Cardiology
(2 times)
|
CTEPH (1 time)
PAH (1 time)
PEA (1 time)
|
2017 Prognostic relevance of pulmonary arterial compliance after therapy initiation or escalation in patients with pulmonary arterial hypertension.
|
| 22 |
Ca-bound phosphorous
(1 time)
|
Environmental Health
(1 time)
|
---
|
2020 Species of iron in the sediments of the Yellow River and its effects on release of phosphorus.
|
| 23 |
calcium phosphorus
(1 time)
|
Environmental Health
(1 time)
|
BP (1 time)
TP (1 time)
TPM (1 time)
|
2019 Distribution of phosphorus species and their release risks in the surface sediments from different reaches along Yellow River.
|
| 24 |
calcium propionate
(1 time)
|
Environmental Health
(1 time)
|
LAB (1 time)
SL (1 time)
|
2010 A ready-to-use antifungal starter culture improves the shelf life of packaged bread.
|
| 25 |
pancreas
(1 time)
|
Gastroenterology
(1 time)
|
GI (1 time)
IORT (1 time)
|
2005 Late complication in patients undergoing pancreatic resection with intraoperative radiation therapy: gastrointestinal bleeding with occlusion of the portal system.
|
| 26 |
Pancreas cancer
(1 time)
|
Antineoplastic Agents
(1 time)
|
DCR (1 time)
FFX (1 time)
GNP (1 time)
|
2022 FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer.
|
| 27 |
paracancerous
(1 time)
|
Genetic Phenomena
(1 time)
|
CDS (1 time)
GC (1 time)
m6A (1 time)
|
2020 The N6-Methyladenosine Features of mRNA and Aberrant Expression of m6A Modified Genes in Gastric Cancer and Their Potential Impact on the Risk and Prognosis.
|
| 28 |
paracancerous tissue
(1 time)
|
Endocrine System Diseases
(1 time)
|
CAFs (1 time)
LN (1 time)
MFECs (1 time)
|
2021 Single-Cell Transcriptomic Analysis of Ecosystems in Papillary Thyroid Carcinoma Progression.
|
| 29 |
paracellular calcium permeability
(1 time)
|
Chemistry
(1 time)
|
PT (1 time)
TAL (1 time)
|
2020 Claudin-12 Knockout Mice Demonstrate Reduced Proximal Tubule Calcium Permeability.
|
| 30 |
partly controlled asthma
(1 time)
|
Allergy and Immunology
(1 time)
|
ACQ (1 time)
CA (1 time)
FCa (1 time)
|
2014 Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: A cluster-randomized trial in primary care.
|
| 31 |
pathologically confirmed as prostate cancer
(1 time)
|
Reproductive Medicine
(1 time)
|
BPH (1 time)
IPSS (1 time)
LUTS (1 time)
|
2013 [Application value of diagnostic TURP for patients with serum PSA abnormality].
|
| 32 |
pathologically organ-confined cancer of the prostate
(1 time)
|
Nephrology
(1 time)
|
RRP (1 time)
|
2011 Residual prostatic tumour in the surgical bed following radical prostatectomy in organ-confined prostate cancer: possible prognostic significance.
|
| 33 |
pathophysiological characterization of the immunological layer of cancerous
(1 time)
|
Biochemistry
(1 time)
|
BPH (1 time)
|
2016 The prostate cancer immunome: In silico functional analysis of antigenic proteins from microarray profiling with IgG.
|
| 34 |
patients are still found with nodal involvement when considering prostate
(1 time)
|
Neoplasms
(1 time)
|
RCC (1 time)
|
2019 Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer.
|
| 35 |
patients diagnosed withprostate cancer
(1 time)
|
Clinical Trials as Topic
(1 time)
|
ADT (1 time)
CV (1 time)
ID (1 time)
|
2020 Cardiovascular Risk Profile in Prostate Cancer Patients Treated with GnRH Agonists versus Antagonists: An Italian Real-World Analysis.
|
| 36 |
patients with clinical or biochemical suspicion forprostate cancer
(1 time)
|
Diagnostic Imaging
(1 time)
|
CS (1 time)
|
2019 MRI-TRUS fusion guided prostate biopsy - initial experience and assessment of the role of contralateral lobe systematic biopsy.
|
| 37 |
PCa without metastasis
(1 time)
|
Urology
(1 time)
|
BPH (1 time)
PSA (1 time)
VTN (1 time)
|
2016 Evaluation of Vitronectin Expression in Prostate Cancer and the Clinical Significance of the Association of Vitronectin Expression with Prostate Specific Antigen in Detecting Prostate Cancer.
|
| 38 |
pelvic cancer treatments, specifically prostate
(1 time)
|
Urologic Diseases
(1 time)
|
FU (1 time)
RCa (1 time)
URF (1 time)
|
2018 Management of iatrogenic urorectal fistulae in men with pelvic cancer.
|
| 39 |
peripheral cancerous
(1 time)
|
Diagnostic Imaging
(1 time)
|
ADC (1 time)
ANOVA (1 time)
AUC (1 time)
|
2013 Diffusion-weighted signal models in healthy and cancerous peripheral prostate tissues: comparison of outcomes obtained at different b-values.
|
| 40 |
PET-detected lesions were most often confirmed to be malignant
(1 time)
|
Medicine
(1 time)
|
BCR (1 time)
PSA (1 time)
PSMA (1 time)
|
2020 Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.
|
| 41 |
PET/CT diagnosis ofprostate cancer
(1 time)
|
Diagnostic Imaging
(1 time)
|
Ga-68 PSMA (1 time)
|
2016 Nuclear Medicine Imaging of Prostate Cancer.
|
| 42 |
phosphorus, calcium
(1 time)
|
Veterinary Medicine
(1 time)
|
PHY (1 time)
|
2019 Phytate degradation in gnotobiotic broiler chickens and effects of dietary supplements of phosphorus, calcium, and phytase.
|
| 43 |
Piper cabralanum
(1 time)
|
Biology
(1 time)
|
OSCC (1 time)
PA (1 time)
PC (1 time)
|
2018 Cytotoxicity and selectiveness of Brazilian Piper species towards oral carcinoma cells.
|
| 44 |
Pituitary carcinomas
(1 time)
|
|
---
|
2020 Malignancy course of pituitary adenoma in MEN1 syndrome: Clinical-Neuroradiological signs.
|
| 45 |
plasma concentrations of calcium
(1 time)
|
General Surgery
(1 time)
|
---
|
1984 [Primary hyperparathyroidism. Lack of effect of cimetidine on plasma levels of parathyroid hormone and calcium].
|
| 46 |
plastocyanin a
(1 time)
|
Biochemistry
(1 time)
|
PC (1 time)
PCb (1 time)
pI (1 time)
|
1990 Microheterogeneity of parsley plastocyanin.
|
| 47 |
Pogostemon cablin
(1 time)
|
Complementary Therapies
(1 time)
|
CRC (1 time)
|
2020 Extract of Pogostemon cablin Possesses Potent Anticancer Activity against Colorectal Cancer Cells In Vitro and In Vivo.
|
| 48 |
positive for cancer
(1 time)
|
Pathology
(1 time)
|
---
|
2015 Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling.
|
| 49 |
preference factors
(1 time)
|
Chemistry
(1 time)
|
MAS (1 time)
MD (1 time)
NMR (1 time)
|
2015 Na/Ca Intermixing around Silicate and Phosphate Groups in Bioactive Phosphosilicate Glasses Revealed by Heteronuclear Solid-State NMR and Molecular Dynamics Simulations.
|
| 50 |
presence of cancer
(1 time)
|
Urology
(1 time)
|
---
|
2008 Clinical assessment of the cancer diagnostic value of prostatic zinc: a comprehensive needle-biopsy study.
|
| 51 |
primary cancers after prostate cancer
(1 time)
|
Neoplasms
(1 time)
|
NPCR (1 time)
|
2012 Primary cancers before and after prostate cancer diagnosis.
|
| 52 |
promote its use amongprostate cancer
(1 time)
|
Urology
(1 time)
|
ADT (1 time)
APA (1 time)
|
2019 [Patients with prostate cancer treated by androgen deprivation therapy: Impact of adapted physical activity].
|
| 53 |
promoting cancer
(1 time)
|
Biochemistry
(1 time)
|
CM (1 time)
|
2018 Comparative Secretome Profiling and Mutant Protein Identification in Metastatic Prostate Cancer Cells by Quantitative Mass Spectrometry-based Proteomics.
|
| 54 |
prostate adenocarcinoma specimens
(1 time)
|
Biochemistry
(1 time)
|
13-HODE (1 time)
|
1997 Production of 13-hydroxyoctadecadienoic acid (13-HODE) by prostate tumors and cell lines.
|
| 55 |
Prostate cancer is
(1 time)
|
|
DNMT (1 time)
EZH2 (1 time)
|
2020 Epigenetic regulation of prostate cancer.
|
| 56 |
prostate carcinogenesis
(1 time)
|
Genetics
(1 time)
|
SPDEF (1 time)
|
2014 SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene.
|
| 57 |
prostate development and cancer
(1 time)
|
Urology
(1 time)
|
AR (1 time)
AREs (1 time)
ARORs (1 time)
|
2008 Inhibition of AR-mediated transcription by binding of Oct1 to a motif enriched in AR-occupied regions.
|
| 58 |
protein C activity
(1 time)
|
Neoplasms
(1 time)
|
5-FU (1 time)
FPA (1 time)
PSag (1 time)
|
1990 Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin.
|
| 59 |
PubMed abstracts applied to prostate
(1 time)
|
Medical Informatics
(1 time)
|
BCa (1 time)
EMU (1 time)
|
2010 Toward an automatic method for extracting cancer- and other disease-related point mutations from the biomedical literature.
|
| 60 |
pulmonary capillary a wave
(1 time)
|
Pulmonary Medicine
(1 time)
|
LV (1 time)
LV pre a (1 time)
PA (1 time)
|
1975 Assessing left ventricular filling pressure with flow-directed (Swan-Ganz) catheters. Detection of sudden changes in patients with left ventricular dysfunction.
|
| 61 |
pulmonary compliance
(1 time)
|
Cardiology
(1 time)
|
CpcPH (1 time)
DPG (1 time)
HFrEF-PH (1 time)
|
2017 Haemodynamic effects of an acute vasodilator challenge in heart failure patients with reduced ejection fraction and different forms of post-capillary pulmonary hypertension.
|
| 62 |
pulmonary vascular compliance
(1 time)
|
Cardiology
(1 time)
|
DPG (1 time)
HF (1 time)
HFpEF (1 time)
|
2017 Pulmonary hemodynamics in heart failure patients with reduced or preserved ejection fraction and pulmonary hypertension: Similarities and disparities.
|
| 63 |
significant-prostate-cancer
(1 time)
|
Neoplasms
(1 time)
|
AUC (1 time)
mpMRI (1 time)
|
2022 Classification of Clinically Significant Prostate Cancer on Multi-Parametric MRI: A Validation Study Comparing Deep Learning and Radiomics.
|
A Search Service for Abbreviation / Long Form